Truist Securities on Maze Therapeutics (MAZE): observed activity in AMKD patients 'encouraging'
Tweet Send to a Friend
Truist Securities analyst Danielle Brill reiterated a Buy rating and $68.00 price target on Maze Therapeutics (NASDAQ: MAZE)The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
